PolyPeptide Group Past Earnings Performance
Past criteria checks 0/6
PolyPeptide Group's earnings have been declining at an average annual rate of -47.6%, while the Life Sciences industry saw earnings growing at 16.5% annually. Revenues have been growing at an average rate of 9.2% per year.
Key information
-47.6%
Earnings growth rate
-96.2%
EPS growth rate
| Life Sciences Industry Growth | 17.6% |
| Revenue growth rate | 9.2% |
| Return on equity | -13.5% |
| Net Margin | -16.1% |
| Next Earnings Update | 13 Aug 2024 |
Recent past performance updates
Recent updates
Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
Mar 14
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Mar 13PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 18Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Mar 23Revenue & Expenses BreakdownBeta
How PolyPeptide Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 320 | -51 | 42 | 1 |
| 30 Sep 23 | 300 | -44 | 41 | 1 |
| 30 Jun 23 | 279 | -37 | 40 | 1 |
| 31 Mar 23 | 280 | -14 | 40 | 1 |
| 31 Dec 22 | 281 | 8 | 41 | 1 |
| 30 Sep 22 | 281 | 20 | 40 | 1 |
| 30 Jun 22 | 281 | 33 | 40 | 1 |
| 31 Mar 22 | 281 | 40 | 36 | 1 |
| 31 Dec 21 | 282 | 47 | 32 | 1 |
| 30 Sep 21 | 277 | 48 | 31 | 1 |
| 30 Jun 21 | 271 | 48 | 29 | 1 |
| 31 Mar 21 | 248 | 40 | 28 | 1 |
| 31 Dec 20 | 224 | 31 | 28 | 1 |
| 31 Dec 19 | 203 | 26 | 25 | 1 |
| 31 Dec 18 | 181 | 24 | 24 | 12 |
Quality Earnings: PPGN is currently unprofitable.
Growing Profit Margin: PPGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PPGN is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.
Accelerating Growth: Unable to compare PPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PPGN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: PPGN has a negative Return on Equity (-13.49%), as it is currently unprofitable.